신경 바이오마커 시장(2024-2028년)

The neurological biomarkers market is forecasted to grow by USD 7.82 bn during 2023-2028, accelerating at a CAGR of 13.01% during the forecast period. The report on the neurological biomarkers market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of neurological disorders, growth in clinical trials for neurological disease-specific biomarkers, and increasing initiatives and support from governments to improve neurological healthcare access.

Technavio's neurological biomarkers market is segmented as below:

By End-user

• Hospitals
• Clinical diagnostic centers
• Research organizations and others

By Indication

• AD
• PD
• ASD
• MS
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the increasing focus on accurate neurological diagnostics as one of the prime reasons driving the neurological biomarkers market growth during the next few years. Also, growing availability of blood-based biomarkers and evolution of manual miRNA will lead to sizable demand in the market.

The report on the neurological biomarkers market covers the following areas:

• Neurological biomarkers market sizing
• Neurological biomarkers market forecast
• Neurological biomarkers market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurological biomarkers market vendors that include Abbott Laboratories, ACROBIOSYSTEMS INC., Advanced Brain Monitoring Inc., Alseres Pharmaceuticals Inc, Bio Rad Laboratories Inc., bioMerieux SA, Charles River Laboratories International Inc., EATRIS ERIC, Eli Lilly and Co., Enzo Biochem Inc., F. Hoffmann La Roche Ltd., Fujirebio Holdings Inc., IQVIA Holdings Inc., Merck KGaA, Metabolon Inc., PerkinElmer Inc, Proteome Sciences plc, QIAGEN NV, Quanterix Corp., and Thermo Fisher Scientific Inc.. Also, the neurological biomarkers market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global neurological biomarkers market 2018 - 2022
• 4.2 End-user Segment Analysis 2018 - 2022
• 4.3 Indication Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by End-user

• 6.1 Market segments
• 6.2 Comparison by End-user
• 6.3 Hospitals - Market size and forecast 2023-2028
• 6.4 Clinical diagnostic centers - Market size and forecast 2023-2028
• 6.5 Research organizations and others - Market size and forecast 2023-2028
• 6.6 Market opportunity by End-user

7 Market Segmentation by Indication

• 7.1 Market segments
• 7.2 Comparison by Indication
• 7.3 AD - Market size and forecast 2023-2028
• 7.4 PD - Market size and forecast 2023-2028
• 7.5 ASD - Market size and forecast 2023-2028
• 7.6 MS - Market size and forecast 2023-2028
• 7.7 Others - Market size and forecast 2023-2028
• 7.8 Market opportunity by Indication

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 Germany - Market size and forecast 2023-2028
• 9.9 UK - Market size and forecast 2023-2028
• 9.10 China - Market size and forecast 2023-2028
• 9.11 France - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Abbott Laboratories
• 12.4 ACROBIOSYSTEMS INC.
• 12.5 Alseres Pharmaceuticals Inc
• 12.6 Bio Rad Laboratories Inc.
• 12.7 bioMerieux SA
• 12.8 Eli Lilly and Co.
• 12.9 F. Hoffmann La Roche Ltd.
• 12.10 IQVIA Holdings Inc.
• 12.11 Merck KGaA
• 12.12 Metabolon Inc.
• 12.13 PerkinElmer Inc
• 12.14 Proteome Sciences plc
• 12.15 QIAGEN NV
• 12.16 Quanterix Corp.
• 12.17 Thermo Fisher Scientific Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations